Billerud AB (publ) BILL
Email when the signal or risk changes · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more
The news check keeps the assessment current.
General analysis — not personal advice.
Wait/hold until Q2 provides clearer evidence on European margin trajectory; consider adding only after confirmed impact from price increases and the cost program. De-risk if Europe margins remain near zero despite actions.
Stable cash flow development, return to profit and new product launches support the continued HOLD signal after the Q3 report.
Sentiment has strengthened after the report beat expectations on both sales and earnings, especially in Europe.
HOLD is the call. Positive is the market mood. Medium risk means some things can go wrong.
Latest change
- 23 Oct 2026 — Report showed higher revenue and profit than expected, driven by Europe margin recovery and new products.
About the company
Billerud AB (publ) manufactures fiber-based packaging materials and paper, with production in Sweden, Finland and the US. Performance is split: North America is strong while Europe is pressured by weak demand and overcapacity. The company is running a cost-savings program targeting full run-rate impact by late 2026.
Bull case
Product launches and margin recovery in Europe can broaden the customer base and support profitability.
Bear case
Uncertain demand in Europe and underperformance in North America may limit upside.
Why this signal
Stable cash flow development, return to profit and new product launches support the continued HOLD signal after the Q3 report.
Recent news
Billerud published the Q3 report on 22 October with net sales of SEK 10,166 million, adjusted EBITDA of SEK 1,032 million beating expectations and net income of SEK 212 million. The stock rose about 3 % on the report day to SEK 85.70. New products Billerud Flute® and PharmaKraft™ were launched. Analysts from ABG and Handelsbanken raised the target price to SEK 100 with buy ratings.